Monthly Factsheet | 31 AUGUST 2024

For professional and accredited investors only. Not for further distribution. Marketing communication. Refer to the Fund prospectus, KID/KIID and/or offering documents before making investment decisions.

WELLINGTON MANAGEMENT[®]

Wellington Global Health Care Equity Fund

USD S Accumulating Unhedged

SUMMARY RISK INDICATOR



Capital at risk: please refer to the bottom of this page for details about the Summary Risk Indicator

MORNINGSTAR[™] RATING*: ★★★★

MORNINGSTAR™ MEDALIST RATING:

×	Silver
---	--------

Analyst-Driven %: 55 Data Coverage %: 100 Morningstar Medalist Date: 31 July 2024

FUND DETAILS

Fund Incep	tion: November 2000
Share Class	s Inception: October 2003
Fund Asset	s: USD 2.6 billion
NAV: USD 9	4.88
Currency H	edging Type: Unhedged
KEY INF	ORMATION
Domicile: In	reland
Regulatory	Regime: UCITS
Legal Struc	ture: Public Limited Company
Dealing Fre	quency: Daily
Country Re	gistration: Austria, Denmark, Germany, Ireland, Italy,
Netherland	s, Portugal, Singapore *, South Korea, Spain, Switzerland
United King	dom.
ISIN: IE00E	0590K11
*Restricted so	heme

FUND CHARACTERISTICS

Asset-Weighted Market Capitalisation:	USD 225.5 billion
Beta (3 Yr):	0.99
Tracking Risk (3 Yr, Annualised):	5.6%
Turnover:	44.0%

FEES AND PRICING

Minimum Investment: USD 1 million Management Fee: 1.25% p.a.

Ongoing Charges Figure *: 1.33%

*The ongoing charges figure excludes Fund transaction costs, except in the case of depositary fees and an entry/exit charge paid by the Fund when buying or selling Shares in another collective investment undertaking. A detailed description of the charges that apply is set out in the section "Charges and Expenses" in the Prospectus. The ongoing charges figure may change over time. Charges applied will reduce the return potential of investments. investments. | If an investor's own currency is different from the currency shown, costs could increase or decrease due to currency or exchange related fluctuations.

For more information, please visit www.wellingtonfunds.com

SUMMARY OF INVESTMENT OBJECTIVE AND POLICY

The Wellington Global Health Care Equity Fund seeks long-term total returns in excess of the MSCI World Health Care Index. The Investment Manager will actively manage the Fund, seeking to achieve the objective by investing in the equity securities of health care companies worldwide. The Fund takes a long term value approach and seeks to invest in fundamentally sound companies.


FUND PERFORMANCE (%)

Past performance does not predict future returns.

TOTAL RETURNS NET OF FEES AND EXPENSES

TOTAL RETORNS NET OF TELS AND	LAFLINGLO						
	YTD	1 MO	3 MOS	1 YR	3 YRS	5 YRS	10 YRS
USD S Acc	16.0	5.4	11.4	21.0	1.9	10.4	9.5
MSCI World Health Care NET	17.6	5.5	11.0	20.5	5.7	12.3	9.3

CALENDAR YEAR RETURNS



DISCRETE ANNUAL PERFORMANCE

									SEP '15 - AUG '16	
USD S Acc	21.0	7.2	-18.4	16.7	32.9	-7.3	15.3	18.4	-4.7	25.6
MSCI World Health Care NET	20.5	10.1	-11.0	23.5	22.4	0.3	13.4	10.8	-1.0	9.9

Past results are not necessarily indicative of future results and an investment can lose value.

The inception date of the USD S Acc share class is 31 October 2003. I Periods greater than one year are annualised. I fian investor's own currency is different from the currency in which the fund is denominated, the investment return may increase or decrease as a result of currency fluctuations. I Fund returns shown are net of USD S Acc share class fees and expenses. Fund returns shown are net of actual (but not necessarily maximum) withholding and capital gains tax but are not otherwise adjusted for the effects of taxation and assume reinvestment of dividends and capital gains. The index returns, where applicable, are shown net of maximum withholding tax and assume reinvestment of dividends. I Please note the fund has a swing pricing mechanism in place. Index - MSCI. If the last business day of the month is not a business day for the Fund, performance is calculated using the last available NAV. This may result in a performance differential between the fund and the index. I Surve: Fund. Wellington Management index. I Source: Fund - Wellington Management.

FUND MANAGEMENT



ι

N

Rebecca Sykes, CFA 19 years of experience

Welington Management Company LLP (WMC) is an independently owned investment advisor registered with the US Securities and Exchange Commission. WMC, along with its affiliates (collectively, Welington Management), provides investment and investment advisory services to institutions around the world. This material and its contents may not be reproduced or distributed, in whole or in part, without the express written consent of Wellington Management. Nothing in this document should be interpreted as advice, nor is it a recommendation to buy or sell shares in Wellington Management Funds (Ireland) plc (the Fund. Investment in the Fund may not be suitable for all investors. Fund shares are made available only in jurisdictions where such offer or solicitation is lawful. Please read the latest Key Information Document (KID), Prospectus, and latest annual report) foror investing. For each country where the Fund is registered for sale, the prospectus, complaints procedure and summary of investor rights in English, and the KID in English and an official language (for Belgium: Dutch, French and German), are available for e of charge from the Funds Transfer Agent State Street Fund Services (Ireland) Limited, 78 Sir John Rogerson's Quay, Dublin 2, Ireland and from https://sites.wellington.com/KIIDS_wmf/Countries/belgium.html. Complaints can be submitted to the Complaints Officer at the address of the Funds Transfer Agent or by email to WellingtonGlobalTA@statestreet.com. The Fund support and vegitade as a UCITS scheme by the Central Bank of Ireland. The Fund may decide to terminate marketing arrangements for shares in an EU Member State by giving 30 working days' notice. I In Switzerland, the Fund Offering documents can be obtained from the local Representative and Paying Agent, BNP Paribas Securities Services, Selnaustrasse 16, 8002 Zurich, Switzerland. The Prospectuses are available in English. I Morningstar rating transfer agent or sup damages or losses arising from any use of the there, (ine, and the yead or inka-duints d Wellington Management Company LLP (WMC) is an independently owned investment adviser registered with the US Securities and Exchange Commission. WMC, along with its affiliates (collectively, Wellington Management), provides investment management and refer to page 2 for more details about risks

Monthly Factsheet Wellington Global Health Care Equity Fund | USD S Accumulating Unhedged

WHAT ARE THE RISKS?

CAPITAL: Investment markets are subject to economic, regulatory, market sentiment and political risks. All investors should consider the risks that may impact their capital, before investing. The value of your investment may become worth more or less than at the time of the original investment. The Fund may experience a high volatility from time to time.

CONCENTRATION: Concentration of investments within securities, sectors or industries, or geographical regions may impact performance.

CURRENCY: The value of the Fund may be affected by changes in currency exchange rates. Unhedged currency risk may subject the Fund to significant volatility.

EQUITIES: Investments may be volatile and may fluctuate according to market conditions, the performance of individual companies and that of the broader equity market.

HEDGING: Any hedging strategy using derivatives may not achieve a perfect hedge.


MANAGER: Investment performance depends on the investment management team and their investment strategies. If the strategies do not perform as expected, if opportunities to implement them do not arise, or if the team does not implement its investment strategies successfully; then a fund may underperform or experience losses.


SMALL AND MID-CAP COMPANY: Small and mid-cap companies' valuations may be more volatile than those of large cap companies. They may also be less liquid.

SUSTAINABILITY: A Sustainability Risk can be defined as an environmental, social or governance event or condition that, if it occurs, could cause an actual or potential material negative impact on the value of an investment.

Before subscribing, please refer to the Fund offering documents/prospectus for further risk factors and pre-investment disclosures. For the latest NAV, please visit www.fundinfo.com.

REGIONAL DISTRIBUTION





16.2

15

0

Benchmark

30

45

60

Totals may not add up to 100% due to rounding.

TOP 10 HOLDINGS

COMPANY NAME	MARKET	INDUSTRY	% OF EQUITY
Eli Lilly & Co	United States	Pharma, Biotech & Life Sciences	9.1
UnitedHealth Group	United States	Health Care Equipment & Services	7.1
Novo Nordisk A/S	Denmark	Pharma, Biotech & Life Sciences	5.4
AstraZeneca PLC	United Kingdom	Pharma, Biotech & Life Sciences	4.4
Merck & Co	United States	Pharma, Biotech & Life Sciences	4.1
Novartis AG	Switzerland	Pharma, Biotech & Life Sciences	2.8
Danaher Corp	United States	Pharma, Biotech & Life Sciences	2.7
Boston Scientific	United States	Health Care Equipment & Services	2.5
Intuitive Surgical	United States	Health Care Equipment & Services	2.2
Argenx SE	Belgium	Pharma, Biotech & Life Sciences	2.2
Total of Top 10			42.5
Number of Equity Names			99

The individual issuers listed should not be considered a recommendation to buy or sell. The weightings do not reflect exposure gained through the use of derivatives. Holdings vary and there is no guarantee that the Fund currently holds any of the securities listed. Please refer to the annual and semi-annual report for the full holdings.

In the following countries, this material is provided by: Canada: Wellington Management Canada ULC, a British Columbia unlimited liability company registered in the provinces of Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland and Labrador, Nova Scotia, Ontario. Prince Edward Island, Quebec, and Saskatchewan in the categories of Portfolio Manager and Exempt Market Dealer. UK: Wellington Management International Limited (WML), authorised and regulated by the Financial Conduct Authority (Reference number: 208573). Europe (ex. UK and Switzerland): marketing entity Wellington Management Europe GmbH which is authorised and regulated by the German Federal Financial Services Authority ("DFA"). To the extent this document relate or any vay to German relation rampices for Wellington Management IUFC) Limited (WM DIFC), a time registered in the DIFC with number 7181 and regulated by the Dubai Financial Services Authority ("DFA"). To the extent this document relates any steps to verify the information sector approval by the DFS A has no responsibility for rejueiting or verifying any prospectus or other documents in connection with any financial product to which this document nay tepts to verify the information set out in this document, and has no responsibility for it. Any financial product to which this document relates may be elliquid and/or subject to sociated documents nor taken any steps to verify the information set out in this document, and has no responsibility for it. Any financial product to which this document is provided on the desist that you are a Professional Client and that you will not copy, distribute or otherwise make this material available to any person. Hong Kong: Wellington Management (Shangha) Limited (WM Hong Kong). a corporatial adviser. This document is provided on the assest danagement (Shangha) Limited (WM Hong Kong). Proge Cleaning in futures contraiscion to conduct type 2 (dealing in futures contraiscions). And they appendent (Shangha) Limited (WPFM), which is an unregulated o

SECTOR DISTRIBUTION

Biopharma Mid Cap

Biopharma Small Cap

Totals may not add up to 100% due to rounding

Fund